147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
Download
More posts

Mouse anti mouse ccl5 monoclonal antibody (clone 2e9)

Mouse monoclonal antibody directed against mouse CCL5. Antibody was produced by immunising CCL5 KO mice with recombinant CCL5. […]

Establishment of redifferentiated cells after treatment of neoplastic

When undifferentiated, invasive neoplastic cell lines are treated with an optimal time / concentration combination of curcumin (under conditions […]

Rat mesothelial cell line f1-1

Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 292 days of induction with crocidolite […]

Rat mesothelial cell line f1-3

Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 307 days of induction with crocidolite […]

Rat mesothelial cell line f1-2

Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 306 days of induction with crocidolite […]

Rat mesothelial cell line f2-0

Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 347 days of induction with crocidolite […]

Rat mesothelial cell line f2-1

Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 298 days of induction with crocidolite […]

Rat mesothelial cell line f2-5

Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 347 days of induction with crocidolite […]

More posts

You might also be interested in